MERIBANKBIOTECH Business Summary

Meribank Biotech Co., Ltd. (4724.TWO) is a specialized biotechnology firm headquartered in Taipei, Taiwan, primarily focused on the cryopreservation and therapeutic application of stem cells. The company generates revenue through a service-based model, charging fees for the detection, extraction, and long-term storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells (MSCs), and adult peripheral blood stem cells. Its operations are divided into two core segments: the Stem Cell Department, which manages the storage and application services, and a Research and Development arm dedicated to advancing allogeneic MSC manufacturing and regenerative medicine. As the first provider in Taiwan to receive FDA certification for its cell storage services, Meribank maintains a high-end market position. It competes directly with other Taiwan-listed healthcare and genomic firms such as Medical Imaging Corporation (6637.TW), Ma Kuang Healthcare Holding (4139.TW), Concord Medical (6518.TW), and TCI GENE (6879.TW), distinguishing itself through its rigorous international quality standards and specialized focus on MSC technologies. The company is currently led by Chairman Chang Yu Hsuan and CEO (General Manager) Jian-Fang Cai, who also serves as Vice Chairman. Meribank's strategic direction is heavily influenced by its founding pedigree; it was acquired and scaled by Meridigen Biotech Co., Ltd., an organization founded by semiconductor veteran John Hsuan (Min-Chih Hsuan), the former Vice Chairman of United Microelectronics Corporation (UMC). This lineage provides the company with significant institutional backing and a deep network within Taiwan’s high-tech and venture capital sectors. Meridigen Biotech remains the company’s largest shareholder, ensuring a stable ownership structure as Meribank transitions from a storage-centric business to a clinical-stage developer of stem cell-based therapeutics for neurological and pulmonary conditions.